Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial t-PA infusion during mechanical thrombectomy in acute ischemic stroke (VANISH)
2023-510374-13-00Phase 3Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of patients achieving modified Rankin Scale (mRS) 0–1. Planned start May 2024; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2023-510374-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510374-13-00.